Sino-Singapore Jingwei Client, November 13th. On the morning of the 13th, the A-shares opened collectively lower. The Shanghai Index reported 3,327.23 points, a decrease of 0.34%; the Shenzhen Component Index reported 13,755.29 points, a decrease of 0.27%; the GEM index reported 2,699.52 points, a decrease of 0.04. %; SSE 50 Index was 3376.91 points, a decrease of 0.6%; CSI 300 reported 4,886.98 points, a decrease of 0.44%.
Shanghai and Shenzhen stock market opening performance source: Wind
On the disk, the beverage manufacturing sector led the decline. Liquor stocks recovered significantly, with Jinhuijiu, Kouzijiao, and Shuijingfang leading the decline; in addition, mining services, hotel and catering, insurance, aquaculture, semiconductors, and brokerage sectors were the leading decliners.
A few sectors such as automobiles, home textiles and nonferrous metals rose.
In terms of concept stocks, titanium dioxide, yesterday's connected board, shared bicycles, and driverless cars ranked among the top gainers; artemisinin, beer, machine vision, EDA design software, edge computing, etc. top decliners.
In terms of individual stocks, 1108 individual stocks rose, among which many stocks such as Longzi, Suguang, Daye Intelligent, etc. rose by more than 5%; 2235 stocks fell, of which Shandong Fiberglass, Digital China, and China Mobile Communications fell. The amplitude exceeds 5%.
Junshi Bio opened 5.26% lower and quoted at 72.00 yuan.
The stock announced in the morning that the company is concerned about the company’s history of the company, foreign cooperation, safety data and research and development progress of the core product Teriplizumab injection, etc. The content is reported.
After confirmation, the company believes that the media article’s report on the company and related persons is completely inaccurate, and is seriously inconsistent with and contrary to objective facts; the company will retain legal means to pursue accountability for institutions, media and individuals that fabricate and spread false reports right.
On the evening of the 12th, Junshi Biology received an inquiry letter from the Shanghai Stock Exchange, focusing on the safety and effectiveness of the main product of Junshi Biology, teripril monoclonal antibody injection, the company's performance structure, and the situation of the R&D team.
In comparison, on the previous trading day (12th), liquor stocks made strong efforts in late trading. Seven stocks including Golden Seed Liquor, Jinhui Liquor, Yilite, Highland Barley Liquor, ST Shede, etc. closed their daily limit. Shunxin Agriculture and Kouzijiao rose. Over 7%, only Wuliangye fell slightly.
China Merchants Securities said that liquor surpassed market expectations to lead the market upward, food returned to normal growth, stock prices rose and fell mixed, and companies damaged by the epidemic gradually recovered.
The third quarterly report is a key node for the full-year performance and the valuation outlook for the coming year. It is recommended to lay out the new year's market for liquor. The valuation of liquor is still improving and the performance is gradually improving.
Chuancai Securities said that with the intensification of market competition and the upgrading of consumption structure, the concentration continues to increase, and the price of high-end liquor continues to rise to open up the room for price increase. Price has become the main driving force, and mid-to-high-end liquor will develop steadily.
At the same time, some people in the industry pointed out the risk that liquor stocks have repeatedly strengthened recently, mainly due to lack of market themes and excessive capital involvement. From the perspective of industry segments, the rise of liquor stocks may have come to an end.
(The opinions in the article are for reference only and do not constitute investment advice. Investment is risky and you need to be cautious when entering the market.)